Clinical Trial Update: Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users [Phase 3]

View source ↗

Summary

Phase III randomized trial comparing low-dose tamoxifen to placebo in hormone replacement therapy users for breast cancer risk reduction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tamoxifen (low-dose) (tamoxifen)

Snippet

Sponsor: European Institute of Oncology | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN